Sofusa

Sofusa is a biotechnology company and a division of Sorrento Therapeutics that specializes in a proprietary lymphatic drug delivery platform. The Sofusa technology utilizes a nano-structured microneedle system designed to deliver biologics, such as monoclonal antibodies, directly into the lymphatic capillaries. This approach aims to bypass systemic blood circulation, potentially enhancing therapeutic efficacy and reducing off-target toxicity by delivering drugs directly to the site of immune activity. The company's clinical pipeline includes programs for rheumatoid arthritis and various oncology indications, leveraging established biologics like etanercept and checkpoint inhibitors. By targeting the lymphatic system, Sofusa seeks to optimize the concentration of therapeutic agents where immune responses are initiated.